IND-Enabling Toxicology Programs

Chapter

Abstract

The challenge of drug discovery and drug development to the pharmaceutical ­toxicologist is that a drug is supposed to have a biological function and requires a scientific understanding of mechanistically based toxicity. Furthermore, drug development allows the toxicologist become somewhat flexible in developing the toxicology program that allows the entry into early stage clinical trials.

Keywords

Toxicity Filtration Lymphoma Estrogenic Creatinine 

References

  1. Berliner, VR. (1974) US Food and Drug Administration requirements for toxicity testing of contraceptive products. In: Briggs MH, Diczbalusy E, eds. Pharmacological models in contraceptive development. Acta Endocrinol (Copenhagen) supp. 185; 240–253.Google Scholar
  2. Burns, J. (1983) Overview of safety regulations governing food, drug and cosmetics. In: Homberger F, Ed., The United States in safety and evaluation and regulation of chemicals 3: interface between law and science. New York: Karger, 1983.Google Scholar
  3. DeGeorge, J., Ahn, C., Andrews, P., Bower, M., Giorgio, D., Goheer, M., Lee-Yam, D., McGuinn, W., Schmidt, W., Sun, C., and Tripathi, S. (1998) Regulatory Considerations for the Preclinical Development of Anticancer Drugs. Cancer Chemother. Pharmacol. 41, 173–185.CrossRefPubMedGoogle Scholar
  4. Gad, S.C. (2009) Drug Safety Evaluation, 2nd ED. New York: Wiley-Interscience.Google Scholar
  5. Goldenthal, E. (1968) Current view on safety evaluation of drugs. FDA Papers, 13–18.Google Scholar
  6. Hastings, K.L. (2007) Nonclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals. FDA www.fda.gov.Google Scholar
  7. Hood, R.D. (2006) Developmental and Reproductive Toxicology: a practical approach, 2nd ED. Taylor & Francis, Philadelphia.Google Scholar
  8. ICH (2001) International Conference on Harmonization: Safety Pharmacology Studies for Human Pharmaceuticals, S7A.Google Scholar
  9. ICH (2008) M3 (R2) Non-Clinical Safety Studies for the Conduct of Human Clinical Trials for PharmaceuticalsGoogle Scholar
  10. Mathieu, M. (2005) New drug development: A regulatory overview. 7th edition. Parexel, Waltham, MA.Google Scholar
  11. Schacter, E. and DeSantis, P. (1998) Labeling of Drug and Biologic Products for Pediatric Use. Drug Information Journal 32, 299–303.Google Scholar
  12. Swidersky, P. (2007). Quality assurance and good lab practice. Contract Pharma. www.­contractpharma.com.

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Gad Consulting ServicesCaryUSA

Personalised recommendations